BCG Plus Mitomycin Shows Similar Efficacy, Fewer Doses in NMIBC
The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.
Related Articles
D-VRd Improves PFS & MRD Negativity in Transplant-Eligible NDMM
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Relatlimab/Nivolumab Fails to Improve RFS in Resected Melanoma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Larotrectinib Shows Durable Responses, Safety in TRK Fusion Thyroid Carcinoma
An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.
Fruquintinib Combo Active in HER2– Gastric/GEJ Cancer
Fruquintinib with chemotherapy and PD-1 blockade showed promising efficacy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Zipalertinib Offers Promising Oral Option for EGFR Exon 20+ NSCLC
Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.
COMRADE Trial: Olaparib Plus Radium-223 Improves rPFS Survival in CRPC
In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual…
FDA Receives Vepdegestrant NDA for ESR1-Mutated Breast Cancer
A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing promising trial results.
IMNN-001 Plus Chemo Improves Survival in Ovarian Cancer
Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.
Zipalertinib’s Efficacy in EGFR ex20ins NSCLC With Brain Mets
Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this…
ARASTEP Trial: Darolutamide for High-Risk Prostate Cancer Recurrence
The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.